Next steps for the CONVERT trial in LS-SCLC
Clinical implications of CTCs in prostate cancer – are they the best thing to measure?
The importance of knowing the molecular profile of a patient's tumor
Pembrolizumab in the treatment of head and neck cancer: is there more to the story?
ESMO 2016: Press brief on the affordability and access to cancer medicines in Europe